-
How do genetic factors guide CLL treatment decisions in the age of targeted therapy?
Time of Update: 2020-07-18
Tausch and his team evaluated the IGHV mutation status, common genomic abnormalities, and gene mutations in 421 untreated patients in the cll14 trial (nct02242942), and compared the efficacy of altuzumab + nitrogen mustard benzoate (gclb) with Veng, which was recently published in the journal blood.
-
Large-scale prospective research analysis shows that if you quit smoking, limit alcohol and eat more garlic, you will not have stomach cancer. You have the final say!
Time of Update: 2020-07-18
previous case-control studies based on Linqu population support that smoking rather than alcohol consumption is a risk factor for gastric cancer.
this large-scale prospective study analysis once again supports smoking as a risk factor for gastric cancer incidence and mortality.
-
Congratulations to Vannosi! The first original new drug was successfully approved for clinical use.
Time of Update: 2020-07-18
effect fnx006 is a new drug developed by Chengdu van Nux Biomedical Technology Co., Ltd., which is used to treat advanced malignant solid tumors such as triple negative breast cancer and melanoma.
-
Yale University: A combination of quercetal monotherapy and chemotherapy can effectively treat invasive endometrial cancer.
Time of Update: 2020-07-18
corresponding author of the study entitled "randomized phase II trial of carboplatin – paclitaxel compared with carboplatin – paclitaxel – trastuzumab in advanced (stage III – IV) or recurrent urethane serous carcinomas that overexpress HER2 / neu (nct01367002): updated overall survival analysis" "This randomized, multi agency, phase 2 trial studied 58 women with uterine serous carcinoma (USC) whose tumors expressed high levels of HER2, which can cause a variety of cancers," Dr. Santin said.
-
Express . . . Reducing the risk of disease progression in patients with triple-negative breast cancer was reduced by 59%, and innovative antibody conjugate drugs reached stage 3 clinical endpoint.
Time of Update: 2020-07-18
▎ immunomedics announced today that troldvy (sacituzumab govitecan hziy), an antibody coupled drug developed by the company, has reached the primary end point of progression free survival (PFS) in a confirmatory phase 3 ascent clinical trial for patients with metastatic triple negative breast cancer (mtnbc), reducing the risk of disease progression or death by 59%.
-
Express . . . The FDA approves new treatment options for blood cancer by changing intravenous lystoy.
Time of Update: 2020-07-18
▎ editor of the content team of pharmaceutics, the US Food and Drug Administration (FDA) announced today that it has approved the launch of inqovi (decitabine and cedazuridine) tablets developed by Astex pharmaceuticals of Otsuka pharmaceutical company for the treatment of adult patients with myelodysplastic syndrome (MDS) and chronic myelomonocytic leukemia (CMML).
-
A review: Met mutation non-small cell lung cancer latest research progress.
Time of Update: 2020-07-18
Background and methods: This study publishes the results of cohort 6, which includes adult patients with stage IIIB / IV advanced after one treatment with high-level met amplification (GCN ≥ 10) or met 14 exon jump mutation (any GCN), ECoG PS 0 – 1, ALK / EGFR wild type.
-
Chinese scientists have revealed for the first time a panoramic view of the molecules of lung adenocarcinoma.
Time of Update: 2020-07-17
Lung cancer is the highest incidence rate and mortality rate in China and even worldwide. in China, there are more than 700000 lung cancer cases and more than 600000 deaths every year in China. lung a
-
2020 BOC/BOA. Annual progress in liver and bile pancreas research.
Time of Update: 2020-07-17
phase II apact study albumin paclitaxel combined with gemcitabine compared with gemcitabine monotherapy in adjuvant treatment of pancreatic cancer: prognosis in different regions.
-
230,000 studies confirmed the risk of serrated polyps raising the risk of colon cancer, and Professor Huang Xiaojun led the JCO article. Tumor intelligence.
Time of Update: 2020-07-17
Jto: guidelines for diagnosis and management of patients with pulmonary neuroendocrine tumors Chinese Journal of oncology: consensus of clinicopathologists on detection of PD-L1 expression in non-small cell lung cancer in China The journal updated the perspectives column online to report the results of a large retrospective study published on July 7 in gastroenterology, providing more accurate information on the relationship between serrated polyps (SP) and the risk of colon cancer.
-
The efficacy of imartinib treatment of glioblastoma was not obvious.
Time of Update: 2020-07-17
There is still a lack of special treatment for glioblastoma (GBM) studies have found that GBM over-expression of a variety of tyrosine kinase receptors is considered to be an important target for ta
-
Sci Adv . . . Liu Bin/Liu Xiaogang/Kong De-ling co-developed a new nanoimmune stimulator to remove malignant solid tumors.
Time of Update: 2020-07-17
After nearly ten years of development, immunotherapy has become one of the most promising methods to cure cancer. however, in the process of immunotherapy, how to avoid excessive activation of immune
-
Lancet . . . Don't eat too much salt, too much salt, too much salt, the Chinese diet caused by cardiovascular disease and cancer deaths in the world's number one.
Time of Update: 2020-07-17
recently, Lancet, a top international medical journal, published an online publication entitled "health effects of dietary risks in 195 countries, 1990 – 2017: a systematic analysis for the global burden of disease study 2017 ", which found that: on a global scale, consumption of almost all healthy foods and nutrients in 2017 was not optimal, especially nuts / seeds, milk and whole grains; globally, dietary risk caused 11 million adult deaths in 2017.
-
Express . . . Sanofi has partnered nearly $1 billion to build a new combination of NK cells/CD38 antibodies against cancer.
Time of Update: 2020-07-17
▎ the editor of the content team of YaoMing Kant today, kiadis Pharma, which is committed to the development of innovative natural killer (NK) cell therapy, announced that it has reached a research and development license agreement with Sanofi company, granting Sanofi the exclusive R & D license for kiadis's previously undisclosed k-nk004 project.
-
Whether the genetic risk is high or low, doing these points can reduce the risk of breast cancer.
Time of Update: 2020-07-17
source: to assess whether a healthy lifestyle can reduce the risk of breast cancer in people with different genetic risks, researchers from the University of Manchester in the UK Pixabay analyzed data from UK Biobank, the largest human genetic cohort sample bank in the world, involving more than 90 thousand female subjects over the age of 40.
-
2020 CSCO BC Conference . . . Fellow Wang Xiaodong: Innovation and Challenge of Biomedicine.
Time of Update: 2020-07-17
basic research and new drug creation: case study -- mechanism of apoptosis induced by estrogen: Academician Wang's research team first found that high concentration of estrogen can induce cell apoptosis in a dose-dependent manner.
-
Immunotherapy re-introduced metastatic renal cell carcinoma, with an efficiency of 23%!
Time of Update: 2020-07-17
In the past five years, several immune checkpoint inhibitors (ICI) have been approved for the treatment of metastatic renal cell carcinoma (mRCC), including navulizumab alone or in combination with epilimumab, pabolizumab + acitinib, avelumab + acitinib.
-
In June, the FDA's cancer drug update.
Time of Update: 2020-07-17
on June 05, FDA approved nivolumab (opdivo) for unresectable patients with advanced recurrent or metastatic esophageal squamous cell carcinoma who previously received fluorouracil and platinum based chemotherapy.
on June 29, FDA awarded the title of pbp-1510 orphan drug for the treatment of pancreatic cancer patients.
-
MHSPC patients appear progress, decisive drug change after the disease control is good! Classic cases.
Time of Update: 2020-07-17
because the patient met the diagnosis of high-risk mhspc, the treatment plan was changed to androgen deprivation therapy (ADT therapy, goserelin) combined with the original research of abiterone + prednisone (AA + P) scheme, and the gastric mucosa protective agent esomeprazole magnesium enteric coated tablets were added after the patients and their families agreed.
-
The Team of Sci Adv Zhou Pingkun found a new mechanism for TIP60 SUMO modification to regulate the selection of DNA double-stranded fracture repair pathways and tumor radiation chemotherapy sensitivity.
Time of Update: 2020-07-17
this study revealed for the first time the role and mechanism of Tip60 in the selection of DNA double strand break repair pathway, and developed new therapeutic targets for tumor radiotherapy and DNA damage chemotherapy drugs such as parpi.